A Study of the Safety and Pharmacokinetics of RO6839921, An MDM2 Antagonist, in Patients With Advanced Cancers, Including Acute Myeloid Leukemia.
Clinical trial NCT02098967 · COMPLETED
Trial details
- NCT number
- NCT02098967
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-04-21
- Primary completion
- 2018-05-07
- Enrollment
- 68
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.